Modern treatment programs for primary Hodgkin's lymphoma and reasons of treatment failure
https://doi.org/10.17650/1818-8346-2007-0-2-24-30
Abstract
Between 1975 and 2005, 566patients (pts) with primary Hodgkin s lymphoma were treated at N.N. Blokhin Cancer Research Center. We analyzed an influence of treatment programs execution on long-term results based on data of treatment efficacy. Median follow-up period was 58 months (range 5 months — 25 years). Deviations of treatment program were registered in 28,6% of pts in cases of execution of full treatment program at Cancer Research Center. The main part of treatment program was performed at Cancer Research Center and the minority of chemotherapy courses was accomplished domiciliary (40,4% pts). In cases of pts examination, choice of therapy and start of treatment at Cancer Research Center, execution of the main part of course was accomplished domiciliary (63,5% pts).
Even increase for more than 6 weeks of the only one interval significantly resulted to reduction of long-term treatment effect. We observed statistically significant decreased of long-term treatment effect in case of reduction the chemotherapy dimension (dose reduction) to 1/3 from predesigned regimen though after achievement of complete remission as well as cancellation of radiotherapy in combined treatment after achievement of complete remission. All deviations indicated above were revealed in 38,8% pts. An exact adherence to modern treatment programs for pts with Hodgkin's lymphoma facilitate to increase effectiveness of therapy.
About the Authors
E. A. DeminaRussian Federation
Moscow
G. S. Tumyan
Russian Federation
Moscow
E. N. Unukova
Russian Federation
Moscow
N. E. Kondratieva
Russian Federation
Moscow
A. G. Borodkina
Russian Federation
Moscow
T. I. Zaitseva
Russian Federation
Moscow
O. M. Meluzova
Russian Federation
Moscow
S. V. Shiriaev
Russian Federation
Moscow
References
1. Hodgkin's disease. P.V. Mauch, J.O. Armitage, V. Diehl et al. (eds) Philadelphia; 1999.
2. Cancer: Principles & Practice of Oncology. Vol. 2. 6th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (eds). Philadelphia, Lippincott-Raven Publishers; 2001. Ch. 45.
3. Raemaekers J.M.M. Treatment of stage I and II Hodgkin's lymphoma. Haematology 2006;2(1):161—5.
4. Klimm B., Engert A. New approaches for patient with advanced-stages and relapsed disease. Haematology 2006;2(1):166—71.
5. Diehl V., Klimm B., Re D. Hodgkin's lymphoma: a curable disease: what comes next? Eur J Haematol 2005;75 (Suppl 66):6—13.
6. Diehl V., Sieber M., Ruffer U. et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997;8:143—8.
7. Horning S., Rosenberg S., Hoppe R. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease. Ann Oncol 1996;7:105—8.
8. 25 Years German Hodgkin Study Group. V. Diehl, A. Josting (eds). Munih, Medizin & Wissen; 2004.
9. Coldman A.J., Goldie J.H. Impact of dose-intensive chemotherapy on the development of permanent drug resistance. Semin Oncol 1987;14(Suppl 4):29—3.
Review
For citations:
Demina E.A., Tumyan G.S., Unukova E.N., Kondratieva N.E., Borodkina A.G., Zaitseva T.I., Meluzova O.M., Shiriaev S.V. Modern treatment programs for primary Hodgkin's lymphoma and reasons of treatment failure. Oncohematology. 2007;(2):24-30. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-2-24-30